These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 35477892)
1. Serum GFAP differentiates Alzheimer's disease from frontotemporal dementia and predicts MCI-to-dementia conversion. Oeckl P; Anderl-Straub S; Von Arnim CAF; Baldeiras I; Diehl-Schmid J; Grimmer T; Halbgebauer S; Kort AM; Lima M; Marques TM; Ortner M; Santana I; Steinacker P; Verbeek MM; Volk AE; Ludolph AC; Otto M J Neurol Neurosurg Psychiatry; 2022 Apr; ():. PubMed ID: 35477892 [TBL] [Abstract][Full Text] [Related]
2. A Combination of Neurofilament Light, Glial Fibrillary Acidic Protein, and Neuronal Pentraxin-2 Discriminates Between Frontotemporal Dementia and Other Dementias. Bolsewig K; Hok-A-Hin YS; Sepe FN; Boonkamp L; Jacobs D; Bellomo G; Paoletti FP; Vanmechelen E; Teunissen CE; Parnetti L; Willemse EAJ J Alzheimers Dis; 2022; 90(1):363-380. PubMed ID: 36120776 [TBL] [Abstract][Full Text] [Related]
3. Plasma GFAP, NfL and pTau 181 detect preclinical stages of dementia. Ingannato A; Bagnoli S; Mazzeo S; Giacomucci G; Bessi V; Ferrari C; Sorbi S; Nacmias B Front Endocrinol (Lausanne); 2024; 15():1375302. PubMed ID: 38654932 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of serum neurofilament light chain and glial fibrillary acidic protein in the diagnosis of Alzheimer's disease. Fang T; Dai Y; Hu X; Xu Y; Qiao J Front Neurol; 2024; 15():1320653. PubMed ID: 38352136 [TBL] [Abstract][Full Text] [Related]
5. Plasma biomarkers for diagnosis of Alzheimer's disease and prediction of cognitive decline in individuals with mild cognitive impairment. Kivisäkk P; Carlyle BC; Sweeney T; Trombetta BA; LaCasse K; El-Mufti L; Tuncali I; Chibnik LB; Das S; Scherzer CR; Johnson KA; Dickerson BC; Gomez-Isla T; Blacker D; Oakley DH; Frosch MP; Hyman BT; Aghvanyan A; Bathala P; Campbell C; Sigal G; Stengelin M; Arnold SE Front Neurol; 2023; 14():1069411. PubMed ID: 36937522 [TBL] [Abstract][Full Text] [Related]
6. Differential levels of plasma biomarkers of neurodegeneration in Lewy body dementia, Alzheimer's disease, frontotemporal dementia and progressive supranuclear palsy. Chouliaras L; Thomas A; Malpetti M; Donaghy P; Kane J; Mak E; Savulich G; Prats-Sedano MA; Heslegrave AJ; Zetterberg H; Su L; Rowe JB; O'Brien JT J Neurol Neurosurg Psychiatry; 2022 Jun; 93(6):651-658. PubMed ID: 35078917 [TBL] [Abstract][Full Text] [Related]
7. FDG-PET and CSF biomarker accuracy in prediction of conversion to different dementias in a large multicentre MCI cohort. Caminiti SP; Ballarini T; Sala A; Cerami C; Presotto L; Santangelo R; Fallanca F; Vanoli EG; Gianolli L; Iannaccone S; Magnani G; Perani D; Neuroimage Clin; 2018; 18():167-177. PubMed ID: 29387532 [TBL] [Abstract][Full Text] [Related]
13. Real-world applicability of glial fibrillary acidic protein and neurofilament light chain in Alzheimer's disease. Parvizi T; König T; Wurm R; Silvaieh S; Altmann P; Klotz S; Rommer PS; Furtner J; Regelsberger G; Lehrner J; Traub-Weidinger T; Gelpi E; Stögmann E Front Aging Neurosci; 2022; 14():887498. PubMed ID: 36072480 [No Abstract] [Full Text] [Related]
14. Improved Accuracy of the Addenbrooke's Cognitive Examination-Revised in the Diagnosis of Mild Cognitive Impairment, Mild Dementia Due to Alzheimer's Disease and Behavioral Variant Frontotemporal Dementia Using Mokken Scale Analysis. Amaral-Carvalho V; Bento Lima-Silva T; Inácio Mariano L; Cruz de Souza L; Cerqueira Guimarães H; Santoro Bahia V; Nitrini R; Tonidandel Barbosa M; Sanches Yassuda M; Caramelli P J Alzheimers Dis; 2024; 100(s1):S45-S55. PubMed ID: 39031367 [TBL] [Abstract][Full Text] [Related]
15. Plasma GFAP in Parkinson's disease with cognitive impairment and its potential to predict conversion to dementia. Tang Y; Han L; Li S; Hu T; Xu Z; Fan Y; Liang X; Yu H; Wu J; Wang J NPJ Parkinsons Dis; 2023 Feb; 9(1):23. PubMed ID: 36759508 [TBL] [Abstract][Full Text] [Related]
16. Serum Beta-Secretase 1 Activity Is a Potential Marker for the Differential Diagnosis between Alzheimer's Disease and Frontotemporal Dementia: A Pilot Study. Saraceno C; Cervellati C; Trentini A; Crescenti D; Longobardi A; Geviti A; Bonfiglio NS; Bellini S; Nicsanu R; Fostinelli S; Mola G; Riccetti R; Moretti DV; Zanetti O; Binetti G; Zuliani G; Ghidoni R Int J Mol Sci; 2024 Jul; 25(15):. PubMed ID: 39125924 [TBL] [Abstract][Full Text] [Related]
17. Differential diagnostic performance of a panel of plasma biomarkers for different types of dementia. Thijssen EH; Verberk IMW; Kindermans J; Abramian A; Vanbrabant J; Ball AJ; Pijnenburg Y; Lemstra AW; van der Flier WM; Stoops E; Hirtz C; Teunissen CE Alzheimers Dement (Amst); 2022; 14(1):e12285. PubMed ID: 35603139 [TBL] [Abstract][Full Text] [Related]
18. Glial Fibrillary Acidic Protein in Serum is Increased in Alzheimer's Disease and Correlates with Cognitive Impairment. Oeckl P; Halbgebauer S; Anderl-Straub S; Steinacker P; Huss AM; Neugebauer H; von Arnim CAF; Diehl-Schmid J; Grimmer T; Kornhuber J; Lewczuk P; Danek A; ; Ludolph AC; Otto M J Alzheimers Dis; 2019; 67(2):481-488. PubMed ID: 30594925 [TBL] [Abstract][Full Text] [Related]
19. Plasma biomarkers of neurodegeneration in mild cognitive impairment with Lewy bodies. Hamilton CA; O'Brien J; Heslegrave A; Laban R; Donaghy P; Durcan R; Lawley S; Barnett N; Roberts G; Firbank M; Taylor JP; Zetterberg H; Thomas A Psychol Med; 2023 Dec; 53(16):7865-7873. PubMed ID: 37489795 [TBL] [Abstract][Full Text] [Related]
20. Blood biomarkers in mild cognitive impairment patients: Relationship between analytes and progression to Alzheimer disease dementia. Silva-Spínola A; Lima M; Leitão MJ; Bernardes C; Durães J; Duro D; Tábuas-Pereira M; Santana I; Baldeiras I Eur J Neurol; 2023 Jun; 30(6):1565-1573. PubMed ID: 36880887 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]